Cystic Fibrosis and associated Complications

被引:4
|
作者
Schwarz, C. [1 ]
Staab, D. [1 ]
机构
[1] Charite, Campus Virchow Klinikum, Christiane Herzog Zentrum, Klin Padiatrie MS Pneumol & Immunol,Sekt Cyst Fib, D-13353 Berlin, Germany
来源
INTERNIST | 2015年 / 56卷 / 03期
关键词
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; TRANSMEMBRANE CONDUCTANCE REGULATOR; FLUID; ANTIBIOTICS; MAINTENANCE; MORTALITY; CHILDREN; EFFICACY; MUTATION; THERAPY;
D O I
10.1007/s00108-014-3646-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cystic fibrosis (CF) is an autosomal recessive inherited metabolic disease. The mutation is located on the long arm of chromosome 7. Due to a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, chloride ion transport is reduced across the cell membrane. As a result, the disease can be described as an exocrinopathy. In all organs with exocrine glands, disorders occur in association with the defective chloride transport. The main impact of this defect is manifested in the lungs. Therefore, the most common cause of death is pulmonary disease with respiratory insufficiency due to recurrent infections. Unfortunately, a cure for the disease is still not available. However, new therapies that may affect the CFTR mutation more specifically give new hope for better therapeutic options in the future. The long-term goal of therapy is to develop a causal therapy for all six different mutation classes and thus for about 2000 mutations.
引用
收藏
页码:263 / 273
页数:11
相关论文
共 50 条
  • [11] Oxygen therapy for cystic fibrosis
    Elphick, Heather E.
    Mallory, George
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07):
  • [12] Drug treatment of cystic fibrosis
    Bruorton, Matthew
    Goddard, Thomas
    AUSTRALIAN PRESCRIBER, 2022, 45 (05) : 171 - 175
  • [13] A Historical Perspective of Cystic Fibrosis
    Wilmott, R. W.
    HONG KONG JOURNAL OF PAEDIATRICS, 2016, 21 (04) : 280 - 285
  • [14] Risk factors for totally implantable venous access device-associated complications in cystic fibrosis
    McCarthy, C.
    O'Carroll, O.
    O'Brien, M. E.
    McEnery, T.
    Franciosi, A.
    Gunaratnam, C.
    McElvaney, N. G.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 (02) : 429 - 434
  • [15] PLEURO-PULMONARY COMPLICATIONS IN PATIENTS WITH CYSTIC FIBROSIS
    Balanetchi, Ludmila
    Selevestru, Rodica
    Gudumac, Eva
    Sciuca, Svetlana
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [16] Extra-Pulmonary Complications in Cystic fibrosis.
    Cohen-Cymberknoh, Malena
    PEDIATRIC PULMONOLOGY, 2021, 56 : S60 - S61
  • [17] CONCURRENT COMPLICATIONS OF ASPERGILLUS FUMIGATUS IN A PATIENT WITH CYSTIC FIBROSIS
    Triggs, Connor
    CHEST, 2023, 164 (04) : 1346A - 1347A
  • [18] Cystic fibrosis associated with liver disease
    Debray, D.
    ARCHIVES DE PEDIATRIE, 2012, 19 : S23 - S26
  • [19] Neutropenia associated with the use of cefepime in pediatric patients with cystic fibrosis
    Hernandez, Ruben
    Delpiano, Luis
    Amador, Jorge
    Arias, Mariana
    Carrasco Delgado, Juan
    REVISTA CHILENA DE INFECTOLOGIA, 2019, 36 (01): : 112 - 114
  • [20] Cystic fibrosis
    O'Sullivan, Brian P.
    Freedman, Steven D.
    LANCET, 2009, 373 (9678) : 1891 - 1904